19 results on '"Manegold, C."'
Search Results
2. 9172 Analysis of biomarkers (BMs) in the AVAiL phase III randomised study of first-line Bevacizumab (Bv) with cisplatin-gemcitabine (CG) in patients (pts) with non-small cell lung cancer (NSCLC)
3. 9144 Cetuximab in combination with gemcitabine/docetaxel or carboplatin/gemcitabine in chemonaïve patients with advanced non-small cell lung cancer: toxicity data from an ongoing Phase II/III trial (GemTax IV)
4. 9056 Evaluating the efficacy of zoledronic acid for the prevention of disease progression in patients with non-small cell lung cancer (NSCLC)
5. 9009 A meta-analysis of four randomized phase II/III trials adding cetuximab to platinum-based chemotherapy as 1st-line treatment in patients with non-small cell lung cancer (NSCLC)
6. 6570 POSTER Results for progression-free survival (PFS) from two randomised, double-blind, multicentre phase III studies of bevacizumab in combination with platin-based chemotherapy in patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC) are comparable when analysed by similar populations and methodology
7. 6571 POSTER Open-label study of pemetrexed (P) alone or in combination with a platinum in patients (pts) with peritoneal mesothelioma (PM): results from the international expanded access program (EAP)
8. 6533 POSTER Cetuximab attenuates EGF induced u-PAR expression in NSCLC
9. 6532 POSTER Zoledronic acid reduces invasion of different lung cancer cell lines
10. 6526 POSTER Review of pulmonary haemorrhage (PH) in non-small cell lung cancer (NSCLC) subjects receiving bevacizumab and cisplatin plus gemcitabine on protocol BO17704
11. 6518 ORAL Subgroup results from a randomised, double-blind, multicentre phase III study of bevacizumab in combination with cisplatingemcitabine in chemotherapy-naive patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC): study BO17704
12. 6509 ORAL Management of hypertension (HTN) in patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC) receiving first-line cisplatin and gemcitabine with bevacizumab or placebo – results from randomised phase III trial BO17704
13. 6503 ORAL Efficacy and safety results from BO17704, a randomised, placebo-controlled phase III study of bevacizumab in combination with cisplatin and gemcitabine in patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC)
14. 6502 ORAL Pre-operative chemotherapy in patients with resectable non-small cell lung cancer (NSCLC): The MRC LU22/ NVALT 2/EORTC 08012 multi-centre randomised trial
15. 1BA Phase III study of pemetrexed plus cisplatin versus gemcitabine plus cisplatin in chemonaive patients with locally advanced or metastatic non-small cell lung cancer (NSCLC)
16. 57 Pemetrexed vs docetaxel: a phase III study in patients with advanced non-small cell lung cancer (NSCLC) who were previously treated with chemotherapy
17. 827 A phase II randomized study comparing docetaxel/clsplatin induction therapy followed by thoracic radiotherapy with or without weekly docetaxel in unresectable stage IIIA–IIIB non-small cell lung cancer.
18. 815 Elderly patients (pts) with unresectable localised or metastatic non-small-cell-lung-cancer (NSCLC): results of a phase II study with oral navelbineâ (nvb) given as a weekly monotherapy and first line treatment.
19. 774 Quality of life assessment and final results of a randomized Phase II study with single-agent gemcitabine and docetaxel given sequentially every 3 weeks show effective treatment in advanced NSCLC.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.